# AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

- Link: https://www.directorstalkinterviews.com/astrazeneca-s-imfinzi-improves-disease-free-survival-in-high-risk-nmibc/4121195945
- Published: 2025-05-09T07:29:42+01:00
- Author: Amilia Stone

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Imfinzi_ regimen demonstrated statistically significant and clinically meaningful
improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer
in POTOMAC Phase III trial.

_Patients lived significantly longer without high-risk disease recurrence or progression
after one year of Imfinzi treatment plus Bacillus Calmette-Guérin (BCG) induction
and maintenance therapy vs. BCG alone _

Positive high-level results from the POTOMAC Phase III trial showed one year of 
treatment with AstraZeneca’s _Imfinzi_ (durvalumab) plus standard-of-care BCG induction
and maintenance therapy demonstrated a statistically significant and clinically 
meaningful improvement in disease-free survival (DFS) for patients with high-risk
non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance
therapy alone.​  

The trial was not statistically powered to formally test overall survival (OS) however
a descriptive analysis demonstrated no detriment.  

More than 70% of bladder cancer patients are diagnosed with NMIBC, an early-stage
cancer where the tumour is in the tissue that lines the inner surface of the bladder
but has not invaded the muscle wall.^(1-2) About half of patients with NMIBC are
classified as high-risk for disease progression or recurrence because of certain
characteristics of their cancer, such as tumour grade, stage and specific tumour
features.^(3)  

> **Maria De Santis, MD, Head of the Interdisciplinary Uro-Oncology Section at Charité
> Universitätsmedizin Berlin, Germany, and a principal investigator in the POTOMAC
> trial, said**: “These exciting data show that adding one year of durvalumab to
> the current standard treatment significantly extends the time patients live without
> high-risk disease recurrence or progression. While most patients with non-muscle
> invasive bladder cancer are treated with curative intent, 80 per cent see their
> disease return and almost half may require life-altering surgery to remove the
> bladder, underscoring the urgent need to improve treatment.” 

> **Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer,
> AstraZeneca, said**: “The positive results for _Imfinzi_ in the POTOMAC trial represent
> a significant advance that will potentially allow more patients with early-stage
> bladder cancer to benefit from this important immunotherapy. Building on the NIAGARA
> data, this outcome demonstrates our strategy of bringing novel therapies to patients
> with early-stage disease where there is the greatest potential for long-term benefit.”

The safety and tolerability of _Imfinzi_ plus BCG induction and maintenance therapy
was consistent with the known safety profiles of the individual medicines, with 
no new safety concerns identified. The addition of _Imfinzi_ did not compromise 
patients’ ability to complete BCG induction and maintenance therapy. 

The second experimental arm evaluating _Imfinzi_ plus BCG induction-only therapy
compared to BCG induction and maintenance therapy alone did not meet the endpoint
of DFS. 

These data will be presented at a forthcoming medical meeting and shared with global
regulatory authorities. 

_Imfinzi_ is approved in the US and other countries for patients with muscle-invasive
bladder cancer (MIBC) based on results from the NIAGARA Phase III trial and continues
to be investigated across early and late-stage bladder cancer in various treatment
combinations, including in patients with MIBC who are ineligible or refuse to take
cisplatin (VOLGA) and in locally advanced or metastatic disease (NILE). 

References

 1. Fuge O, et al. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65-79.
 2. American Cancer Society. What Is Bladder Cancer? Available at: https://www.cancer.
    org/cancer/bladder-cancer/about/what-is-bladder-cancer.html. Accessed May 2025.

AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated
clinical areas of high unmet medical need. The Company has a comprehensive and diverse
IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion
of the anti-tumour immune response and stimulate the body’s immune system to attack
tumours. 

Share on:
